Abstract

Protein glycosylation governs key physiological and pathological processes in human cells. Aberrant glycosylation is thus closely associated with disease progression. Mass spectrometry (MS)-based glycoproteomics has emerged as an indispensable tool for investigating glycosylation changes in biological samples with high sensitivity. Following rapid improvements in methodologies for reliable intact glycopeptide identification, site-specific quantification of glycopeptide macro- and micro-heterogeneity at the proteome scale has become an urgent need for exploring glycosylation regulations. Here, we summarize recent advances in N- and O-linked glycoproteomic quantification strategies and discuss their limitations. We further describe a strategy to propagate MS data for multilayered glycopeptide quantification, enabling a more comprehensive examination of global and site-specific glycosylation changes. Altogether, we show how quantitative glycoproteomics methods explore glycosylation regulation in human diseases and promote the discovery of biomarkers and therapeutic targets.

Highlights

  • Continuous developments in mass spectrometry (MS) technologies, glycopeptide enrichment, and database search algorithms have significantly improved the coverage and reliability of the identification of intact glycopeptides in complex biological samples [6,7], omitting the need for separate analyses of chemically or enzymatically released oligosaccharides and de-glycosylated peptides [8]. Such improvements in intact glycopeptide analysis preserve the information of protein-glycan linkages and increase the range of applications of glycoproteomics to complex biological samples

  • Stadlmann et al developed a comparative glycoproteomics platform combining a new N-glycopeptide identification algorithm, SugarQb, with the quantitative workflows embedded in Proteome Discoverer [25]

  • The inherent complexity of glycosylation limits the direct application of the well-developed quantitative methods for large-scale intact glycopeptide quantification

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Continuous developments in MS technologies, glycopeptide enrichment, and database search algorithms have significantly improved the coverage and reliability of the identification of intact glycopeptides in complex biological samples [6,7], omitting the need for separate analyses of chemically or enzymatically released oligosaccharides (glycome) and de-glycosylated peptides (de-glycoproteome) [8] Such improvements in intact glycopeptide analysis preserve the information of protein-glycan linkages and increase the range of applications of glycoproteomics to complex biological samples. Despite this progress, the robust and reliable. Intact glycopeptide analysis allowsand quantification at the glycosite (macro-heterogeneity), glycoform (micro-heterogeneity) glycan levels. We summarize recent glycoproteomics studies in human disease and highlight the importance of quantitative glycoproteomics in biomarker and therapeutic target discovery

Methods
13 C media yeast
Labeling-Based Quantification
Isobaric Chemical Labeling
Isotopic Chemical Labeling
Metabolic Labeling
Enzymatic Labeling Using 18 O Stable Isotope
Glycan Labeling
Label-Free Quantification
DDA-Based Label Free Quantification
DDA-Based
Multi-Layered Quantification of Glycoproteome
Multi-layered
Cancers and Other
SARS-CoV-2
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call